Bradbury; Robert Hugh
Patent Applications and Registrations
Patent applications and USPTO patent grants for Bradbury; Robert Hugh.The latest application filed is for "1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases".
Company Profile
5.19.41
- Bradbury; Robert Hugh - Cambridge GB
- Bradbury; Robert Hugh - Cheshire GB
- Bradbury; Robert Hugh - Macclesfield GB
- Bradbury; Robert Hugh - Macklesfield GB
- Bradbury, Robert Hugh - Macclesfield Cheshire GB
Patent Activity
| Patent | Date |
|---|---|
| [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases Grant 11,407,755 - Bradbury , et al. August 9, 2 | 2022-08-09 |
| 1,2,4]triazolo[4,3-b]pyridazines For Use In The Treatment Of Proliferative Diseases App 20210107905 - BRADBURY; Robert Hugh ; et al. | 2021-04-15 |
| [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases Grant 10,766,905 - Bradbury , et al. Sep | 2020-09-08 |
| [1,2,4]triazolo[4,3-b]pyridazines For Use In The Treatment Of Proliferative Diseases App 20200055861 - Bradbury; Robert Hugh ; et al. | 2020-02-20 |
| [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases Grant 10,407,432 - Bradbury , et al. Sept | 2019-09-10 |
| Chemical Compounds App 20190038607 - Bradbury; Robert Hugh ; et al. | 2019-02-07 |
| Chemical compounds Grant 10,130,617 - Bradbury , et al. November 20, 2 | 2018-11-20 |
| [1,2,4]triazolo[4,3-b]pyridazines For Use In The Treatment Of Proliferative Diseases App 20180230158 - BRADBURY; Robert Hugh ; et al. | 2018-08-16 |
| [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases Grant 9,944,650 - Bradbury , et al. April 17, 2 | 2018-04-17 |
| Chemical Compounds App 20170326115 - Bradbury; Robert Hugh ; et al. | 2017-11-16 |
| [1,2,4]triazolo[4,3-b]pyridazines For Use In The Treatment Of Proliferative Diseases App 20170210747 - Bradbury; Robert Hugh ; et al. | 2017-07-27 |
| Chemical compounds Grant 9,616,050 - Bradbury , et al. April 11, 2 | 2017-04-11 |
| Chemical Compounds App 20160136140 - Bradbury; Robert Hugh ; et al. | 2016-05-19 |
| Chemical compounds Grant 9,155,727 - Bradbury , et al. October 13, 2 | 2015-10-13 |
| Chemical Compounds App 20140357661 - BRADBURY; Robert Hugh ; et al. | 2014-12-04 |
| Chemical Compounds - 643 App 20130203714 - Bradbury; Robert Hugh ; et al. | 2013-08-08 |
| 4-anilino quinazoline derivatives as antiproliferative agents Grant 8,399,667 - Bradbury , et al. March 19, 2 | 2013-03-19 |
| Quinazoline Derivatives App 20130005727 - BRADBURY; Robert Hugh ; et al. | 2013-01-03 |
| Quinazoline Derivatives App 20120329795 - Hennequin; Laurent Francois Andre ; et al. | 2012-12-27 |
| Chemical compounds--643 Grant 8,258,140 - Bradbury , et al. September 4, 2 | 2012-09-04 |
| Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 Grant 8,003,649 - Bradbury , et al. August 23, 2 | 2011-08-23 |
| Chemical Compounds 751 App 20100292222 - Bradbury; Robert Hugh ; et al. | 2010-11-18 |
| 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer Grant 7,820,683 - Bradbury , et al. October 26, 2 | 2010-10-26 |
| Chemical Compounds - 643 App 20100267699 - Bradbury; Robert Hugh ; et al. | 2010-10-21 |
| 4-anilino Quinazoline Derivatives As Antiproliferative Agents App 20100152442 - Bradbury; Robert Hugh ; et al. | 2010-06-17 |
| Indolylamino Quinazoline Derivatives As Antitumor Agents App 20100029696 - Bradbury; Robert Hugh | 2010-02-04 |
| Bicyclic Derivatives For Use In The Treatment Of Androgen Receptor Associated Conditions-155 App 20100016279 - Bradbury; Robert Hugh ; et al. | 2010-01-21 |
| Quinazoline derivatives Grant 7,625,908 - Hennequin , et al. December 1, 2 | 2009-12-01 |
| Quinazoline Derivatives As Anticancer Agents App 20090239861 - Bradbury; Robert Hugh | 2009-09-24 |
| Indazolylamino Quinazoline Derivatives As Antitumour Agents App 20090137615 - Bradbury; Robert Hugh | 2009-05-28 |
| 4-(1h-indazol-5-yl-amino)-quinazoline Compounds As Erbb Receptor Tyrosine Kinase Inhibitors For The Treatment Of Cancer App 20090048251 - Bradbury; Robert Hugh ; et al. | 2009-02-19 |
| Quinazoline Derivatives Used As Inhibitors Of Erbb Tyrosine Kinase App 20090029968 - Barlaam; Bernard Christophe ; et al. | 2009-01-29 |
| Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase App 20090023759 - Bradbury; Robert Hugh | 2009-01-22 |
| 4-anilino Quinazoline Derivatives As Antiproliferative Agents App 20080269487 - Bradbury; Robert Hugh ; et al. | 2008-10-30 |
| Quinazoline Derivatives App 20080096881 - Hennequin; Laurent Francois Andre ; et al. | 2008-04-24 |
| Quinazoline Derivatives App 20070244136 - Hennequin; Laurent Francois Andre ; et al. | 2007-10-18 |
| Quinazoline Derivatives as Erbb Receptor Tyrosine kinases App 20070232607 - Bradbury; Robert Hugh ; et al. | 2007-10-04 |
| 4-Anilino-quinazoline derivatives as antiproliferative agents App 20070149546 - Bradbury; Robert Hugh ; et al. | 2007-06-28 |
| Quinazoline derivatives App 20070099943 - Bradbury; Robert Hugh ; et al. | 2007-05-03 |
| Quinazoline derivatives as antitumor agents App 20070088044 - Hennequin; Laurent Francois Andre ; et al. | 2007-04-19 |
| Quinazoline derivatives as antitumor agents App 20070082921 - Hennequin; Laurent Francois Andre ; et al. | 2007-04-12 |
| Quinazoline derivatives App 20070043010 - Bradbury; Robert Hugh ; et al. | 2007-02-22 |
| Quinazoline derivatives App 20070037837 - Hennequin; Laurent Francois Andre ; et al. | 2007-02-15 |
| Quinazoline derivatives as tyrosine kinase inhibitors App 20070032508 - Bradbury; Robert Hugh ; et al. | 2007-02-08 |
| Quinazoline derivatives as antitumor agents App 20070015743 - Bradbury; Robert Hugh ; et al. | 2007-01-18 |
| Quinazoline derivatives Grant 7,148,230 - Bradbury , et al. December 12, 2 | 2006-12-12 |
| 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents Grant 7,067,522 - Pease , et al. June 27, 2 | 2006-06-27 |
| 4-anilino quinazoline derivatives as antiproliferative agents App 20050215574 - Bradbury, Robert Hugh ; et al. | 2005-09-29 |
| Quinazoline derivatives App 20050165035 - Bradbury, Robert Hugh ; et al. | 2005-07-28 |
| 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents App 20050090515 - Pease, Elizabeth Janet ; et al. | 2005-04-28 |
| Quinazoline derivatives as antitumor agents App 20050054662 - Hennequin, Laurent Francois Andre ; et al. | 2005-03-10 |
| 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents Grant 6,838,464 - Pease , et al. January 4, 2 | 2005-01-04 |
| Pyrimidine compounds Grant 6,710,052 - Pease , et al. March 23, 2 | 2004-03-23 |
| 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents Grant 6,649,608 - Pease , et al. November 18, 2 | 2003-11-18 |
| 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents App 20030181474 - Pease, Elizabeth Janet ; et al. | 2003-09-25 |
| 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents App 20030149266 - Pease, Elizabeth Janet ; et al. | 2003-08-07 |
| Pyrimidine compounds App 20030114473 - Pease, Elizabeth Janet ; et al. | 2003-06-19 |
| Aryl-substituted pyrimidine sulphonamide compounds as endothelin antagonists Grant 6,083,951 - Bradbury July 4, 2 | 2000-07-04 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 